INTRODUCTION
Candida spp. infections are recognized as a major challenge in public health, commonly associated with high morbidity and mortality since its diagnosis and treatment present difficulties and high healthcare costs (Colombo et al. 2008 , Gudlaugsson et al. 2003 , Arnold et al. 2010 . In Latin America, mortality rates are usually higher than those observed in the Northern Hemisphere; however, it is worth mentioning that epidemiology of candidemia is poorly studied in this region in comparison to the United States and Europe (Nucci et al. 2013 , Colombo et al. 2008 , Santolaya et al. 2014 .
In Brazil, studies demonstrated that incidence rates of Candida infections are heterogeneous in different regions (Colombo et al. 2006 , Nucci et al. 2010 . There are several studies that focus
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specifically on the Southeast (Colombo et al. 1999 , Costa et al. 2000 , Resende et al. 2002 , de Resende et al. 2006 , Aleva et al. 2007 , Ribeiro et al. 2010 , Oliveira et al. 2014 , Moretti et al. 2013 , Midwest (Leite Junior et al. 2011 , HoffmannSantos et al. 2013 , Akeme Yamamoto et al. 2012 , North-east (Mascarenhas et al. 2012 , Araujo Paulo de Medeiros et al. 2014 , Nascimento Mdo et al. 2014 and South of Brazil (Antunes et al. 2004 , Pasqualotto et al. 2008 , da Costa et al. 2014 . Fluconazole (FCZ) is the first option for prophylaxis and treatment, due to its good tolerance, few side effects and low costs (Li et al. 2014) . However, the widespread and prolonged use of antifungal agents induces tolerance development as well as collateral resistance to other drugs (Prasad and Rawal 2014) . Some species, such as Candida glabrata and Candida krusei, already present decreased susceptibility or resistance to FCZ (Wingard et al. 1991 , Marr et al. 2000 . Preventing the intracellular accumulation of a drug by rapid extrusion of the antifungal agent is a known mechanism of resistance (Prasad et al. 2002) . The overexpression of efflux pumps, such as ATP-binding cassette (ABC) family or major facilitator superfamily (MFS), has been shown to be the cause of resistance in some fungi (Cannon et al. 2009 ).
The aim of this study is to evaluate the frequency of yeast species isolated from urine, faeces, catheter, blood and other secretions, analyze the susceptibility to FCZ as well as investigate the possible mechanism of resistance of clinical strains obtained from the University Hospital of the Federal University of Juiz de Fora, Minas Gerais, Brazil, over a period of two years (2012) (2013) (2014) . The yeast strains grown in YPD medium (2% glucose, 2% peptone, 1% yeast extract) at 37 °C under agitation, were harvested in the exponential phase of growth and stored at 4 °C.
MATERIALS AND METHODS

Yeast strains and Patients
Ninety-three
strain identifiCation
Isolate identification was performed by MALDI Microflex LT (Bruker Daltonics, Bremen, Germany) measurement, according to manufacturer formic acid extraction procedure. Briefly, in this identification method, a single colony of each strain grown overnight on YPD agar was suspended in 300µL of de-ionized water and 900µL of absolute ethanol and centrifuged at 14,462 xg for 2 min. The supernatant was discarded and the pellet was airdried. 1:1 v 70% formic acid and 100% acetonitrile were added to the pellet and vortexed. The samples were centrifuged at 14,462 xg for 2 min, and 1µLof the supernatant was spotted in duplicate onto a steel target and air-dried at room temperature. Before identification, each spot was overlaid with 1µL of HCCA (α-Cyano-4-hydroxycinnamic acid, Bruker) matrix solution saturated with organic solvent (50% acetonitrile and 2.5% trifluoroacetic acid) and air dried completely. The spectra were externally calibrated using standard ATCC Escherichia coli 25922, before plate identification. Raw spectra were processed using MALDI BIOTYPER Realtime Classification software version 3.1 (Bruker Daltonik MALDI Biotyper Since FK506 is a classical ABC transporter inhibitor (Egner et al. 2000) , it was used as an identifier for resistance mediated by these transporters. The "spot test" was used as a measure of growth as previously described by (Reis de Sa et al. 2014 ).
flow CYtometrY assaY
The experiment was performed using eight representative resistant Candida spp. isolates. The cells were incubated overnight in 20 ml of YPD medium 1 x 10³ cells/mL at 37 °C under agitation. After incubation, with a value of 1.0 to 3.0 OD, the cells were centrifuged (5000 x g / 5 min) and washed four times with deionized water. After washing, the strains were maintained on ice for 2h. A concentration of 6 x 10 5 cells/mL were incubated with Rhodamine 6G (R6G) (5µM), an ABC transporter fluorescent substrate (Maesaki et al. 1999) , in the presence or absence of glucose (2%) for 1h, at 37 °C under agitation. The cells were centrifuged (9000 x g / 2 min) and washed with PBS buffer (3 X) before analysis in duplicate by BD Accuri™ C6 Flow Cytometer, in order to measure of R6G efflux by strains. 
RESULTS
CliniCal sourCe analYsis and sPeCies identifiCation
We analyzed a total of 93 Candida spp. isolates in a period of two years (2012) (2013) (2014) . The isolates were collected from different clinical samples as summarized in Table I . Most Candida spp. isolates were detected in urine samples (n=71, 76%). The other samples presented a fewer number of isolates: blood (n=8, 8.6%), catheter (n=5, 5.4%), tracheal secretions (n=4, 4.3%), faeces (n=1, 1.1%), ascetic fluid (n=2, 2.2%), abdominal (n=1, 1.1%) and gastrostomy secretions (n=1, 1.1%).
The MALDI-TOF mass spectrometry method enabled Candida spp. strain identification in eight species: Candida albicans (n=41, 44.1%), Candida tropicalis (n=26, 28%), Candida glabrata (n=14, 15.1%), Candida parapsilosis (n=7, 7.5%), Candida kefyr (n=2, 2.2%), Candida metapsilosis (n=1, 1.1%), Candida krusei (n=1, 1.1%) and Candida lusitaniae (n=1, 1.1%) (Fig. 1) .
Correlating clinical sources and species identification, C. albicans was the most prevalent specie in urine samples (n=34, 48%), followed by C. tropicalis (n=19, 27%) and C. glabrata (n=12, 17%). C. albicans was also prevalent in blood samples (n=3, 37.5%), gastrostomy secretion (n=1, 100%) and tracheal secretions (n=2, 50%) (Fig. 2) .
fluConazole susCePtibilitY
In order to classify susceptible (S), susceptible dose-dependent (SDD) and resistant strains (R), we performed a FCZ susceptibility assay. 58 isolates presented a susceptible profile (62.5%), six were SDD (6.5%) and 29 were selected as resistant to FCZ (31%).
The majority of resistant strains belonged to the C. tropicalis species (n=13, 45%), while C. albicans was the most prevalent susceptible (n=27, 46.6%) and SDD (n=3, 50%) isolate (Table II) . The MIC 50 values of each resistant strain are summarized in Table III . Seven Candida isolates presented MIC 50 higher than the maximum tested concentration: three of these strains were C. tropicalis, two C. albicans and two C. glabrata. Three isolates were resistant to concentrations higher than 500µg/ml, five for 250µg/ml, two for 125µg/ml and eleven for 64µg/ml.
reversion of fluConazole resistanCe
After the screening of clinical strains resistant to FCZ, we performed a chemosensitization assay using FK506 in order to evaluate the possible resistance mechanism of these Candida spp. isolates. The resistance phenotype of 22 clinical strains reverted upon treatment with the ABC transporter inhibitor, while the other seven (1016, 250i, 14A, 163A, 1027, 124i, 1114) isolates remained resistant, even in the presence of FK506 (Fig. 3) . Among the 22 resistant Candida strains chemosentitized by FK506, we observed that 11 were C. tropicalis, seven were C. albicans, 4 C. glabrata.
flow CYtometrY
Flow cytometry assay was performed in order to check the capability to extrude Rhodamine 6G (R6G), a fluorescent substrate pumped by ABC transporters, by resistant strains. For this test, we used four representative strains reverted by FK506 (Fig. 4a ) and four that remained resistant even in the presence of FK506 (Fig. 4b) . The data revealed that strains reverted by FK506 were able to pump out R6G in the presence of glucose whereas strains that displayed high level of resistance to FCZ, even in the presence of FK506, were not able to efflux the fluorescent probe in the presence or absence of glucose. These results confirm those obtained by chemosensitization assay (Fig. 3 ) since reverted strains also presented an efflux of R6G. 
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DISCUSSION
Regional differences in the incidence pattern of antifungal resistance and patient suceptibility can be found when monitoring fungal infections.
Knowledge of the epidemiological characteristics of a certain community has both local and global importance, considering the constant flow of individuals within a country and around the world (Nucci et al. 2010) . Since Candida spp. are the most common fungal nosocomial pathogens, contributing significantly to morbidity and mortality (Wisplinghoff et al. 2014 , Pfaller et al. 2014 , we decided to evaluate the prevalence of Candida infections at a Brazilian University Hospital located in a Southeast region, where no epidemiologic data relating to candidiasis had been previously collected. We also determined the susceptibility profile of Candida spp. strains -isolated from clinical material -as well as the possible role of ABC transporters in the FCZ resistance.
Our results revealed that the Candida species most commonly isolated were C. albicans (44.4%), C. tropicalis (28%) and C. glabrata (14%) (Fig.  1) . These data were consistant with other Brazilian and international studies concerning nosocomial fungal infections, which show C. albicans as the most prevalent species isolated (Wille et al. 2013 , da Costa et al. 2014 , Corzo-Leon et al. 2014 .
Furthermore, we observed a higher proportion of non-albicans species (56%) compared with Candida albicans (44%), a trend which has also been observed in other studies. Oliveira and colleagues evaluated cases of fungemia from 2007 to 2010 and observed a higher prevalence of candidemia caused by Candida species other than C. albicans during a period of four years (Oliveira et al. 2014 ). Moretti and colleagues observed an increasing incidence of candidemia caused by C. Urinary tract infections caused by Candida spp. are commonly observed in hospitalized patients, especially those in intensive care units (Kauffman 2014). The tendency of hospitalized patients to be predisposed to urinary tract infections caused by Candida spp is explained by factors such as instrumentation of the urinary tract, prolonged hospitalization, use of broad spectrum antibiotics and indwelling urinary tract devices (Sobel et al. 2011) . The evaluation of bacteriuria and candiduria in an intensive care unit (ICU), conducted by Aubron and colleagues over a period of six years (2006) (2007) (2008) (2009) (2010) (2011) , demonstrated that Candida spp. represented 55% of pathogens isolated from positive urine cultures (Aubron et al. 2015) . We also observed this high Candida spp. prevalence in urinary tract infections, with 71 of the 93 isolates tested, coming from urine samples (Table I) . Of these, the three most prevalent species were C. albicans (34 / 71 -48%), C. tropicalis (19 / 71 -27%) and C. glabrata (12 / 71 -17%) (Fig. 2) . These data are confirmed by Sobel and colleagues who identify these three species as the main cause of candiduria (Sobel et al. 2011) .
Azoles, specially FCZ, are by far the most commonly used antifungals in clinical practice and the emergence of the resistance to this chemotherapeutic is a concern in clinical practice (Vandeputte et al. 2012) . When assessing the susceptibility profile to FCZ, we observed the resistance phenotype in 32.1% (29/93) of studied Candida strains (Table II) . Our results differ from those obtained by many other studies, which detected a lower incidence of FCZ resistance (Wille et al. 2013 , Tortorano et al. 2012 , Lockhart et al. 2011 , Pfaller et al. 2011 , da Matta et al. 2007 . These studies evaluated a higher number of samples compared to our study, which focused on a more specific population. This could explain the differences concerning the prevalence of resistance to FCZ. However, our results are consistent with other studies (Puig-Asensio et al. 2014 , Tortorano ATHAYDE NEVES-JUNIOR et al. et al. 2012 when it comes to emergence of FCZ resistance in strains of Candida tropicalis and Candida glabrata. We observed that the most prevalent FCZ resistant species were C.albicans (11/29), C.tropicalis (13/29), C. glabrata (4/29) and C. krusei (1/29).
The active transport of azoles out of the cell, mediated by membrane ABC transporters is an important mechanism of resistance in Candida species (Sanglard et al. 2009 ). Therefore, we decided to evaluate the role of ABC transporters in the FCZ resistance expressed by the 29 Candida spp. strains. For this, we used the chemosinsitization experiment with FK506 (tacrolimus), a classic inhibitor of Candida ABC transporters (Cannon et al. 2009 ). We observed that in 75.8% (22/29) (Fig.  3 ) of these strains, FK506 could reverse the FCZ resistance, revealing a probable contribution of ABC transporters to this phenotype of resistance. Among the strains chemosensitized by FK506, we identified 11 C.tropicalis, seven C. albicans and four C. glabrata (Table III) . Other studies also observed the participation of efflux pumps in FCZ resistance in Candida species. White et al. (2002) assessed the mechanism of resistance in C. albicans strains isolated from clinical material and showed that out of 13 strains with a FCZ MIC 50 for > 64µg/mL, six presented overexpression of ABC transporter genes related to resistance to azoles and CaCdr1/CaCdr2 (White et al. 2002) . Evaluating the FCZ resistance mechanism of 20 strains of C. glabrata, Sanguinetti et al. (2005) noted that all FCZ resistant strains showed overexpression of at least one ABC transporter related to antifungal efflux (CgCdr1, CgCdr2 and CgSNQ), and that FK506 could chemosensitize all strains (Sanguinetti et al. 2005) . Barchiesi et al. (2000) demonstrated that prolonged exposure of C. tropicalis to FCZ induced the expression of an ABC transporter that promotes the active efflux of this antifungal (Barchiesi et al. 2000) . It is worth mentioning that seven of the clinical isolates did not present reversion of resistance phenotype using FK506. This data suggest that probably these strains possess other mechanism of resistance. Besides ABC transporters, Candida species can present an overexpression of major facilitator superfamily (MFS) proteins, another efflux pump that actively extrudes substrates using energy from proton gradient across membrane (Cannon et al. 2009 ). Additionally, resistance can be developed through different molecular mechanisms concerning: overexpression and/or mutation of ERG11 as well as alterations in ergosterol biosynthetic pathway (Lamping et al. 2010) . In order to check and reinforce the possible involvement of ABC transporters on resistance phenotype, we also performed an efflux assay using R6G. Clinical isolates reverted by FK506 also extruded part of R6G, while the opposite was observed on strains that maintained resistance even in the presence of the inhibitor. These data corroborate the possible involvement of ABC transporters on resistant profile of those Candida spp. isolates reverted by FK506.
The data obtained so far, reinforce the emergence of FCZ resistant strains of Candida spp. in the hospital environment, as well as the involvement of active drug transporters in resistance phenotype. This phenomenon highlights the need for developing more effective control measures of fungal infections, rational use of antifungal drugs and development of new molecules able to abrogate the active transport of antifungals. 
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RESUMO
A candidíase tem se tornado uma importante preocupação para a prática clínica, especialmente com o aumento da incidência de pacientes imunocomprometidos. Neste cenário, o desenvolvimento da resistência ao fluconazol se apresenta como um desafio ao tratamento dessas infecções oportunistas. O objetivo deste estudo consistiu em avaliar alguns aspectos epidemiológicos das infecções por Candida em um hospital universitário brasileiro, utilizando dados, anteriormente, indisponíveis. Nós observamos que 44% dos 93 isolados clínicos testados pertenciam à espécie Candida albicans e 56%, a espécies Candida não-albicans (principalmente Candida tropicalis e Candida glabrata). A maioria das cepas foi isolada de amostras de urina, onde C. albicans foi predominantemente detectada. 29 cepas apresentaram um fenótipo de resistência ao fluconazol e destas, 22 foram quimiosensibilizadas pelo FK506, um inibidor clássico dos transportadores ABC, envolvidos na resistência aos azóis. Estes dados sugerem a provável participação das bombas de efluxo nesse fenótipo de resistência. Nosso estudo ressalta a necessidade do desenvolvimento de medidas de controle efetivas para as infecções fúngicas, o uso racional de antifúngicos e o desenvolvimento de novas moléculas capazes de inibir o transporte ativo de antifúngicos.
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